Are we making progress in kidney transplantation?

Kristin Mekeel, Herwig Ulf Meier-Kriesche, Bruce Kaplan

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose of review: Renal transplantation has become the preferred treatment modality for patients with end-stage renal disease. Renal transplantation confers both a quality of life and survival advantage over maintenance dialysis. Over the past 50 years tremendous strides have been made in our understanding of the immunobiology of transplantation, leading to the development of newer and more specific immunosuppressive agents. This, along with the advent of improved anti-infective strategies and diagnosis, has led to improvements in acute rejection and in short-term and intermediate-term graft survival. Recent findings: Although early projections appeared to indicate that short-term improvements in allograft survival were leading to improved long-term graft survival, more recent data indicate that long-term graft survival has not followed the salutary change in short-term outcomes. Furthermore, during the past 10 years we have witnessed a remarkable decrease in acute rejection, although clinical trials and registry analysis have failed to offer definite proof that this leads to improved long-term survival. Summary: In the future it will be vital to elucidate further the mechanisms of late allograft injury, and to develop reliable and validated surrogate markers to test new therapies that may improve graft survival.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalCurrent Opinion in Organ Transplantation
Volume11
Issue number1
DOIs
StatePublished - Feb 2006
Externally publishedYes

Fingerprint

Graft Survival
Kidney Transplantation
Allografts
Survival
Immunosuppressive Agents
Chronic Kidney Failure
Registries
Dialysis
Transplantation
Biomarkers
Maintenance
Quality of Life
Clinical Trials
Wounds and Injuries
Therapeutics

Keywords

  • Acute rejection
  • Graft survival
  • Kidney transplant

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Are we making progress in kidney transplantation? / Mekeel, Kristin; Meier-Kriesche, Herwig Ulf; Kaplan, Bruce.

In: Current Opinion in Organ Transplantation, Vol. 11, No. 1, 02.2006, p. 1-6.

Research output: Contribution to journalArticle

Mekeel, Kristin ; Meier-Kriesche, Herwig Ulf ; Kaplan, Bruce. / Are we making progress in kidney transplantation?. In: Current Opinion in Organ Transplantation. 2006 ; Vol. 11, No. 1. pp. 1-6.
@article{e21e3eb2b8dc477386a75b014c16511c,
title = "Are we making progress in kidney transplantation?",
abstract = "Purpose of review: Renal transplantation has become the preferred treatment modality for patients with end-stage renal disease. Renal transplantation confers both a quality of life and survival advantage over maintenance dialysis. Over the past 50 years tremendous strides have been made in our understanding of the immunobiology of transplantation, leading to the development of newer and more specific immunosuppressive agents. This, along with the advent of improved anti-infective strategies and diagnosis, has led to improvements in acute rejection and in short-term and intermediate-term graft survival. Recent findings: Although early projections appeared to indicate that short-term improvements in allograft survival were leading to improved long-term graft survival, more recent data indicate that long-term graft survival has not followed the salutary change in short-term outcomes. Furthermore, during the past 10 years we have witnessed a remarkable decrease in acute rejection, although clinical trials and registry analysis have failed to offer definite proof that this leads to improved long-term survival. Summary: In the future it will be vital to elucidate further the mechanisms of late allograft injury, and to develop reliable and validated surrogate markers to test new therapies that may improve graft survival.",
keywords = "Acute rejection, Graft survival, Kidney transplant",
author = "Kristin Mekeel and Meier-Kriesche, {Herwig Ulf} and Bruce Kaplan",
year = "2006",
month = "2",
doi = "10.1097/01.mot.0000203881.02687.51",
language = "English (US)",
volume = "11",
pages = "1--6",
journal = "Current Opinion in Organ Transplantation",
issn = "1087-2418",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Are we making progress in kidney transplantation?

AU - Mekeel, Kristin

AU - Meier-Kriesche, Herwig Ulf

AU - Kaplan, Bruce

PY - 2006/2

Y1 - 2006/2

N2 - Purpose of review: Renal transplantation has become the preferred treatment modality for patients with end-stage renal disease. Renal transplantation confers both a quality of life and survival advantage over maintenance dialysis. Over the past 50 years tremendous strides have been made in our understanding of the immunobiology of transplantation, leading to the development of newer and more specific immunosuppressive agents. This, along with the advent of improved anti-infective strategies and diagnosis, has led to improvements in acute rejection and in short-term and intermediate-term graft survival. Recent findings: Although early projections appeared to indicate that short-term improvements in allograft survival were leading to improved long-term graft survival, more recent data indicate that long-term graft survival has not followed the salutary change in short-term outcomes. Furthermore, during the past 10 years we have witnessed a remarkable decrease in acute rejection, although clinical trials and registry analysis have failed to offer definite proof that this leads to improved long-term survival. Summary: In the future it will be vital to elucidate further the mechanisms of late allograft injury, and to develop reliable and validated surrogate markers to test new therapies that may improve graft survival.

AB - Purpose of review: Renal transplantation has become the preferred treatment modality for patients with end-stage renal disease. Renal transplantation confers both a quality of life and survival advantage over maintenance dialysis. Over the past 50 years tremendous strides have been made in our understanding of the immunobiology of transplantation, leading to the development of newer and more specific immunosuppressive agents. This, along with the advent of improved anti-infective strategies and diagnosis, has led to improvements in acute rejection and in short-term and intermediate-term graft survival. Recent findings: Although early projections appeared to indicate that short-term improvements in allograft survival were leading to improved long-term graft survival, more recent data indicate that long-term graft survival has not followed the salutary change in short-term outcomes. Furthermore, during the past 10 years we have witnessed a remarkable decrease in acute rejection, although clinical trials and registry analysis have failed to offer definite proof that this leads to improved long-term survival. Summary: In the future it will be vital to elucidate further the mechanisms of late allograft injury, and to develop reliable and validated surrogate markers to test new therapies that may improve graft survival.

KW - Acute rejection

KW - Graft survival

KW - Kidney transplant

UR - http://www.scopus.com/inward/record.url?scp=33644632718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644632718&partnerID=8YFLogxK

U2 - 10.1097/01.mot.0000203881.02687.51

DO - 10.1097/01.mot.0000203881.02687.51

M3 - Article

VL - 11

SP - 1

EP - 6

JO - Current Opinion in Organ Transplantation

JF - Current Opinion in Organ Transplantation

SN - 1087-2418

IS - 1

ER -